Galimedix Therapeutics

About

Headcount over time

Offices

Q&A

What is Galimedix Therapeutics' primary focus?

Galimedix Therapeutics is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies for serious eye and brain diseases, specifically targeting conditions where amyloid beta plays a role, such as dry AMD, glaucoma, and Alzheimer’s disease.

When was Galimedix Therapeutics founded?

Galimedix Therapeutics was founded in June 2017.

How much funding has Galimedix Therapeutics raised to date?

Galimedix Therapeutics has raised a total of $2,000,000.

Which investors participated in Galimedix Therapeutics' funding round in January 2019?

In January 2019, Galimedix Therapeutics received funding from InFocus Capital Partners and Rimonci Capital.

What is the current employee count for Galimedix Therapeutics?

Galimedix Therapeutics has 1-10 employees.

Where is Galimedix Therapeutics headquartered?

Galimedix Therapeutics is headquartered in Shorashim, Israel.

Does Galimedix Therapeutics hold any patents?

Yes, Galimedix Therapeutics holds 1 patent.

Who are the co-founders of Galimedix Therapeutics?

The co-founders of Galimedix Therapeutics are Christopher Parsons, Herman Russ, and Andrew Pearlman.

Team · 13

Alexander Gebauer

Founder · Co-founder, Executive Chairman

Hermann Russ

Founder · Co-founder, Chief Scientific Officer, Board Member

Andrew Pearlman

Founder · Founder, President, Board Member

Phyllis K. Bellin

Founder · Co-founder, Chief Financial Officer, Board Member

Christopher Parsons

Founder · Co-Founder, Chief Pharmacologist & VP of Non-Clinical Development

Yaniv Barkana

Chief Medical Officer

Céline Olmiere

Board Member

Thomas C. Hohman

Board Member

Jeffrey Liebmann

Board Member

Richel Liu

Board Member

Robert Rothman

Board Member

Cary Sucoff

Board Member

Luciana Summo

Vice President, R&D Operations

Sectors & technology

Highlights

Tags